Biodesix Statistics
Total Valuation
Biodesix has a market cap or net worth of $144.33 million. The enterprise value is $178.74 million.
| Market Cap | 144.33M |
| Enterprise Value | 178.74M |
Important Dates
The next confirmed earnings date is Wednesday, May 8, 2024, after market close.
| Earnings Date | May 8, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Biodesix has 114.55 million shares outstanding. The number of shares has increased by 95.03% in one year.
| Shares Outstanding | 114.55M |
| Shares Change (YoY) | +95.03% |
| Shares Change (QoQ) | +15.97% |
| Owned by Insiders (%) | 59.44% |
| Owned by Institutions (%) | 13.73% |
| Float | 39.08M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 2.94 |
| Forward PS | 2.17 |
| PB Ratio | 31.51 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.64 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.19, with a Debt / Equity ratio of 13.25.
| Current Ratio | 1.19 |
| Quick Ratio | 1.02 |
| Debt / Equity | 13.25 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -4.47 |
Financial Efficiency
Return on equity (ROE) is -30,185.80% and return on invested capital (ROIC) is -63.34%.
| Return on Equity (ROE) | -30,185.80% |
| Return on Assets (ROA) | -60.60% |
| Return on Capital (ROIC) | -63.34% |
| Revenue Per Employee | $226,207 |
| Profits Per Employee | -$240,304 |
| Employee Count | 217 |
| Asset Turnover | 0.57 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.25% in the last 52 weeks. The beta is 1.12, so Biodesix's price volatility has been higher than the market average.
| Beta (1Y) | 1.12 |
| 52-Week Price Change | -21.25% |
| 50-Day Moving Average | 1.42 |
| 200-Day Moving Average | 1.54 |
| Relative Strength Index (RSI) | 39.60 |
| Average Volume (30 Days) | 139,619 |
Short Selling Information
The latest short interest is 315,040, so 0.28% of the outstanding shares have been sold short.
| Short Interest | 315,040 |
| Short Previous Month | 277,443 |
| Short % of Shares Out | 0.28% |
| Short % of Float | 0.81% |
| Short Ratio (days to cover) | 1.26 |
Income Statement
In the last 12 months, Biodesix had revenue of $49.09 million and -$52.15 million in losses. Loss per share was -$0.64.
| Revenue | 49.09M |
| Gross Profit | 36.08M |
| Operating Income | -41.34M |
| Pretax Income | -52.15M |
| Net Income | -52.15M |
| EBITDA | -37.10M |
| EBIT | -42.61M |
| Loss Per Share | -$0.64 |
Balance Sheet
The company has $26.28 million in cash and $60.69 million in debt, giving a net cash position of -$34.41 million or -$0.30 per share.
| Cash & Cash Equivalents | 26.28M |
| Total Debt | 60.69M |
| Net Cash | -34.41M |
| Net Cash Per Share | -$0.30 |
| Equity / Book Value | 4.58M |
| Book Value Per Share | 0.04 |
| Working Capital | 6.27M |
Cash Flow
In the last 12 months, operating cash flow was -$22.87 million and capital expenditures -$23.06 million, giving a free cash flow of -$45.93 million.
| Operating Cash Flow | -22.87M |
| Capital Expenditures | -23.06M |
| Free Cash Flow | -45.93M |
| FCF Per Share | -$0.56 |
Margins
Gross margin is 73.50%, with operating and profit margins of -84.22% and -106.23%.
| Gross Margin | 73.50% |
| Operating Margin | -84.22% |
| Pretax Margin | -106.23% |
| Profit Margin | -106.23% |
| EBITDA Margin | -75.59% |
| EBIT Margin | -86.81% |
| FCF Margin | -93.57% |
Dividends & Yields
Biodesix does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -95.03% |
| Shareholder Yield | -95.03% |
| Earnings Yield | -36.13% |
| FCF Yield | -31.82% |
Analyst Forecast
The average price target for Biodesix is $3.50, which is 177.78% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.50 |
| Price Target Difference | 177.78% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Biodesix has an Altman Z-Score of -5.86 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.86 |
| Piotroski F-Score | 3 |